Mutations in ion channel genes can cause a diverse group of phenotypes and play important roles in the filed of monogenic neurological diseases [1] . With the application of Next-generation sequencing, more and more genetic and clinical heterogeneity in monogenic neurological diseases was reported, which improved our understanding of the pathophysiologic mechanisms in different monogenic neurological diseases.
Mutations in ion channel genes can cause a diverse group of phenotypes and play important roles in the filed of monogenic neurological diseases [1] . With the application of Next-generation sequencing, more and more genetic and clinical heterogeneity in monogenic neurological diseases was reported, which improved our understanding of the pathophysiologic mechanisms in different monogenic neurological diseases.
Herein, we report a girl presenting with intractable absence epilepsy, who had a dramatic response to pyridoxine. Using a panel containing 153 epilepsy-related genes based on Next-generation sequencing, a de novo CACNA1A mutation was found coincidentally. Our report expands the clinical spectrum of CACNA1A-related disorders and the genetic spectrum of pyridoxine dependent epilepsy (PDE).
Case report
The patient was born at term after an unremarkable pregnancy and had nearly normal early psychomotor development, although the parents reported that the patient could not run fast like other normal children or speak smoothly. At the age of 3 years, she presented blank episode lasting for 2-3s several times per day. The postural tone was not lost and she was able to resume normal activities immediately. Absence epilepsy was considered after attending to a local hospital and valproic acid (VPA) was used (200 mg per day). However, no improvement was observed and the absence seizure still occured 2-3 times per day. At the age of 5 years, the patient came to our hospital. VPA (500 mg per day) and lamotrigine (LTG) (150 mg per day) were used and the frequency of absence seizure decreased. It only happened when the patient's temperature was above 38 C. At the age of 6 years, the frequency of absence seizure increased without obvious inducement. It occurred 20-30 times per day, accompanying with partial seizures for 3 times in one year, which all presented as right upper limb hold up, eyes looked toward right side and unconsciousness for about 1 min. No episodic attack of ataxia was complained. An ataxic gait was observed, which was considered as antiepileptic drugs (AEDs) induced ataxia at first. On EEG examination, a typical 2.5-3 Hz spike-wave was observed (Fig. 1A) . The diagnosis of absence epilepsy was made based on clinical features and EEG result. Brain MRI at the age of 3 years revealed hippocampal sclerosis on the left side and no obvious cerebellar atrophy. At the age of 10 years, cerebellar atrophy was observed on the sagittal view in the brain MRI (Supplemental data 1). Metabolic tests of blood and urine were all normal, which included normal level of proline in blood. Other blood tests including alkaline phosphatase and Ca 2+ were all within normal range. As pyridoxine was proposed in some intractable epilepsy, 500 mg pyridoxine (Vitamin B 6 , 20 mg/kg) daily was added to current treatment of 750 mg (30 mg/kg) VPA and 150 mg (6 mg/kg) LTG daily. A dramatic improvement was observed that the frequency of absence seizure was less than 10 times on the first day and no absence seizure was observed on the next five days. The pyridoxine withdraw test was positive as the frequency of absence seizure increased (about 30-40 times per day) when we reduced the dose of pyridoxine. After the use of pyridoxine, the background of EEG was also better than that before the use of pyridoxine (Fig. 1B and C) . The patient was discharged with oral drugs containing 750 mg (30 mg/kg) pyridoxine, 500 mg (20 mg/kg) VPA and 50 mg (2 mg/kg) LTG daily. In the next year, with oral drugs containing 200 mg (7.4 mg/ kg) pyridoxine, 500 mg (18 mg/kg) VPA and 50 mg (1.9 mg/kg) LTG daily, she only had absence seizure for 2-3 times per day and one generalized tonic-clonic seizure in this year. The ataxia did not improve or progress and no episodic progress of ataxia was complained. Using a panel containing 153 epilepsy-related genes (Supplemental data 3) based on Next-generation sequencing, a heterozygous missense variant c. 410A>G (p. E137G) in CACNA1A gene was detected in this patient. This variant was further confirmed by Sanger sequencing and not detected in either of the healthy parents, which indicated that this variant was de novo (Supplemental data 2). According to the standards and guidelines of ACMG and MacArthur et al., this variant was evaluated as pathogenic mutation (Supplemental data 4). No pathogenic variant in genes (ALDH7A1,PNPO and PIGV were contained in the panel) responsible for PDE was detected in this patient. Although other two genes (TNSALP and ALDH4A1) responsible for PDE were not sequenced, the normal level of proline and alkaline phosphatase did not support this patient had their responsible phenotypes of hypophosphatasia and hyperprolinemia type 2 [2] . Based on these clinical and genetic studies, we concluded that the mutation c. 410A>G (p. E137G) in CACNA1A gene was the causative mutation in this patient.
Discussion
Mutations in CACNA1A have complicated phenotypic heterogeneity, and mainly cause three allelic disorders: episodic ataxia type 2 (OMIM: 108500), familial hemiplegic migraine type 1 (OMIM: 141500) and spinocerebellar ataxia type 6 (OMIM: 183086) [1] . Epilepsy was reported in about 7% patients of episodic ataxia type 2 [3] . Absence epilepsy with a 3 Hz spikewave EEG pattern was reported as the core symptom in several patients with mutations in CACNA1A. The clinical phenotype of absence epilepsy with ataxia (AEA) was proposed in these patients [4] . According to the clinical features and EEG result of this patient, a diagnosis of AEA should be considered. To our knowledge, there were a total of ten patients with CACNA1A gene mutations experienced absence seizure reported. We reviewed these patients' clinical phenotypes, EEG, brain MRI and drug response of absence seizure ( Table 1) . The response to AEDs in these patients with absence seizure was variable from "seizurefree with VPA and LTG" and "successively treated with VPA, topiramate and levetiracetam" to intractable absence seizure even with two or three conventional AEDs (like VPA and ethosuximide) for absence seizure. It seems that the absence seizure was not easy to be controlled as this type of seizure used to be. This patient presented frequent absence seizure, which was intractable to several AEDs (VPA and LTG). As pyridoxine was proposed in some intractable epilepsy, pyridoxine was used in this patient and a dramatic response was observed clinically and electroencephalographically. The positive result of the pyridoxine withdraw test supported the pyridoxine dependence of the absence epilepsy in this patient.
PDE is characterized by intractable seizures that are not controlled with conventional AEDs but that respond clinically and electroencephalographically to pharmacologic doses of pyridoxine [2] . Autosomal recessive inherited mutations in ALDH7A1 gene were the main genetic defects of PDE. Four other autosomal recessive conditions with seizures responsive to pyridoxine or its vitamers are known: pyridoxal phosphate responsive epileptic encephalopathy (OMIM: 610090, PNPO gene), neonatal/infantile hypophosphatasia (OMIM: 241500, TNSALP gene), familial hyperphosphatasia (OMIM: 239300, PIGV gene) and hyperprolinemia type 2 (OMIM: 239510, ALDH4A1 gene). In this patient, no mutation of ALDH7A1, PNPO and PIGV genes was detected and the tests in blood and urine did not support a clinical diagnosis of neonatal/infantile hypophosphatasia or hyperprolinemia type 2. However, it is a limitation that we did not sequence TNSALP and ALDH4A1 genes.
Although some AEA patients with CACNA1A mutations reported intractable absence seizure, pyridoxine was not used in these patients. We suggested that pyridoxine could be tried as the choice in such patients. Our report expands the clinical spectrum of CACNA1A-related disorders and the genetic spectrum of PDE and more observation was needed to get a more reliable conclusion.
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